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The link between emotion and disease has 
long fascinated mankind. Famous seventeen 
century British physician, Thomas Willis 
(1621–1675) saw diabetes as a consequence 
of sadness or long sorrow (Willis, 1971). 
Though better known for describing what 
eventually became known as the “Circle of 
Willis”, he provided a fairly comprehensive 
description of the role of nervous system 
in disease (Encyclopædia Britannica, 2010). 
Willis may not have been the first to see 
the link, but his account stands out for its 
sophistication. In subsequent years and cen-
turies, psychosomatic medicine has fallen in 
and out of favor many times. Depending on 
whom we ask, and what we focus on, we are 
currently witnessing exciting and challeng-
ing times for psychosomatic research.
Despite decades of work, a key question 
in  psychosomatic  research  remains:  do 
psychiatric disorders cause or contribute 
to physical disease such as heart disease, 
diabetes and asthma? And given the treat-
ments that we have, a second question is: 
does timely and optimum treatment of the 
psychiatric disorders prevent, arrest or roll 
back the progression of physical disease? As 
brain was shown to influence systemic phys-
iology in health, as well as in disease, the 
impact of cognition and emotion, and not 
just psychiatric illness, on general physical 
health became an important line of inves-
tigation. Indeed, there is more to psycho-
somatic research than just psychosomatic 
medicine. With the new interest in positive 
psychology, the impact “positive emotional 
states” such as equanimity, level-headedness 
and congruence is also an important topic 
for investigation.
Among the positive developments are 
many exciting findings from neuroimag-
ing studies as well as the promise of genetic 
studies. Neuroimaging has put “brain” back 
at the center of the psychosomatic medicine 
(Lane et al., 2009). Consequently, models in 
“mind body” medicine are becoming more 
elegant and plausible, and include diverse 
variables  such  as,  mental/psychological/
behavioral states and traits; brain; infor-
mation transfer systems such as autonomic 
nervous system, endocrine, immune; and 
end organ functioning (Lane et al., 2009). 
Imaging studies suggest that brain has a 
role in a wide variety of systemic disorders 
such as irritable bowel syndrome, conver-
sion  disorder,  asthma,  fibromyalgia  and 
pain disorder (Lane and Wager, 2009). The 
evidence of such a role is not surprising, but 
what is striking is the amount of overlap in 
the findings among these seemingly diverse 
conditions. Most of this overlap is appar-
ent in the fronto-limbic structures, such 
as the prefrontal cortex, insula, cingulate, 
orbitofrontal cortex, subcortical areas such 
as amygdala, ventral striatum and hippoc-
ampus. These very structures, notably, also 
seem to have a role in regulating immune 
function,  autonomic  and  endocrine  sys-
tems (Lane and Wager, 2009; McEwen and 
Gianaros, 2010).
With the gradual decrease in the cost 
of conducting neuroimaging studies, it is 
becoming easier to conduct studies that can 
establish potentially causal or mediational 
relationships.
Combining  neuroimaging  and  genet-
ics (Hariri and Weinberger, 2003) has also 
begun  to  pay  dividends.  A  recent  study 
examined the impact of a polymorphism 
within  the  catechol-O-methyltransferase 
(COMT) gene, the Val(108/158)Met poly-
morphism, in conjunction with structural 
and functional neuroimaging; results sug-
gest that the COMT Met allele modulates 
neural substrates of negative versus positive 
emotion processing, and may contribute 
to negativity bias, i.e., tendency to perceive 
danger rather than reward (Williams et al., 
2010). The same group of investigators had 
earlier demonstrated that early life stress 
led to greater negativity bias in those with 
a variant of serotonin transporter linked 
promoter region (5-HTT-LPR Short allele; 
Williams et al., 2009). Since negativity bias 
is generally held as predisposing to anxiety 
and depression, this line of investigation can 
potentially establish polymorphisms with 
the COMT and 5-HTT-LPR genes, as well as 
identify other genes as predisposing factors 
in these psychiatric disorders. Aside from 
elucidating the pathophysiology of psychi-
atric disorders, this line of work may help 
focus the preventative effort to those at the 
greatest  risk.  Since  individuals  with  the 
short allele of 5HTT-LPR also show more 
prominent positron emission tomography 
findings in response to colorectal distention, 
this particular polymorphism may also have 
implications for psychosomatic medicine 
(Fukudo et al., 2009).
The findings from basic research, such 
as  the  growing  understanding  of  the 
link  between  autonomic  system  and  the 
immune system, also strengthen the case for 
psychosomatic research (Oke and Tracey, 
2009). Till now, it was hard to ascertain 
the utility and underlying mechanism for 
complementary  and  alternative  medical 
treatments.  But  over  the  past  decade,  it 
became known that immune system can be 
regulated by the vagus nerve (Tracey, 2007). 
Simultaneously, the role of immune system 
in the pathogenesis of atherosclerosis, type 
2 diabetes, Alzheimer disease, rheumatoid 
arthritis, inflammatory bowel disease, mul-
tiple sclerosis, and sepsis also became clearer 
(Klover et al., 2005; Plomgaard et al., 2005; 
Popa et al., 2007). Now, the evidence that a 
variety of interventions such as hypnosis, 
biofeedback, behavioral modification, cog-
nitive and relaxation therapies can stimu-
late the vagus nerve (Lehrer et al., 2003; 
Peng et al., 2004; Nolan et al., 2010) sets 
the stage for studies that examine whether 
these  interventions  can  also  impact  the 
immune system and thereby, alleviate the 
growing list of disorders believed to have a 
significant inflammatory component (Oke 
and Tracey, 2009).
Despite the positives, many challenges 
remain. Chiefly, translational research is dif-
ficult to conduct, especially when one aims 
to examine the impact of an intervention in 
a disease with long gestation period. Greater 
understanding of the predictors and surro-
gate markers certainly helps. For example, 
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research and new understanding. As it is, 
much of the available literature on these 
disorders is old.
Though,  historically,  psychosomatic 
research has not lived up to its full prom-
ise, the new generation of studies provides 
a strong reason for new optimism. History 
as we know, often teaches us wrong lessons. 
Our challenge is to win back old “believ-
ers” as we attract new ones. There will be 
a continued need to disseminate emerging 
findings among the general public and our 
colleagues in other disciplines. Given strong 
headwinds  such  as  the  recent  economic 
downturn,  convincing  funding  agencies 
to maintain, if not enhance, support for 
psychosomatic research will be a constant 
battle. A related challenge would be attract 
a constant supply of talented and moti-
vated researchers to the field. The onus for 
knowledge dissemination is upon all of us; 
we at the Frontiers in Psychosomatic Research 
promise to do our part. With a few false 
starts and detours, we will get there!
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Apart from the physical disease itself, 
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